Gut Microbiome

Jianchang No. 1 (1) formula alleviates irritable bowel syndrome with diarrhea improving gut microbiota and regulating toll-like receptors/nuclear factor-kappa B signaling pathway in bowel syndrome with diarrhea rats.

TL;DR

Jianchang No. 1 formula maintains intestinal barrier integrity by reshaping gut-microbial diversity and composition, dampening the TLR/NF-κB signaling cascade, and thereby alleviating low-grade colonic inflammation and its attendant clinical symptoms in IBS-D rats.

Key Findings

Jianchang No. 1 treatment restored body weight, lowered fecal water content, and raised the intestinal capacity threshold in IBS-D rats.

  • IBS-D rat models were established through a combination of chronic restraint stress, water avoidance stress, and administration of senna decoction.
  • Body weight, fecal water content (FWC), and intestinal capacity threshold were monitored before and after treatment.
  • These measurements served as primary clinical symptom indicators of IBS-D severity in the rat model.

Jianchang No. 1 enhanced both the richness and composition of the gut microbiota in IBS-D rats.

  • 16S rRNA sequencing technology was employed to assess the abundance and compositional shifts within the gut microbiota.
  • The formula reshaped gut-microbial diversity and composition as part of its mechanism of action.
  • Gut microbiota modulation was identified as a key mechanism underlying the therapeutic effects of Jianchang No. 1.

Jianchang No. 1 upregulated tight-junction proteins zonula occludens-1 (ZO-1) and occludin, indicating improved intestinal barrier integrity.

  • Gene and protein expression in colonic samples were determined using quantitative real-time PCR, Western blot, and immunofluorescence.
  • Upregulation of ZO-1 and occludin was associated with maintenance of intestinal barrier integrity.
  • Barrier integrity restoration was mechanistically linked to the dampening of TLR/NF-κB signaling and reshaping of gut microbiota.

Jianchang No. 1 downregulated the LPS-TLR2/4-MyD88-NF-κB signaling axis in IBS-D rats.

  • Serum levels of lipopolysaccharide (LPS) and LPS content in colon tissue were measured using enzyme-linked immunosorbent assay (ELISA).
  • The formula simultaneously downregulated myeloid differentiation factor 88 (MyD88) and nuclear factor kappa B (NF-κB) components of the signaling cascade.
  • Toll-like receptor 2 and toll-like receptor 4 were both implicated in the signaling pathway suppressed by treatment.
  • Dampening of the TLR/NF-κB signaling cascade was identified as a central mechanism alleviating low-grade colonic inflammation.

Jianchang No. 1 reduced pro-inflammatory cytokines and modulated additional immune mediators in IBS-D rats.

  • Downstream pro-inflammatory mediators interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were downregulated.
  • Interleukin-4 (IL-4) and interferon-gamma (IFN-γ) were also downregulated following treatment.
  • The anti-inflammatory cytokine interleukin-10 (IL-10) was upregulated, indicating a shift toward an anti-inflammatory state.
  • Cytokine expression was assessed in colonic samples using quantitative real-time PCR and Western blot.

Pathological examination of colon tissue showed improvements following Jianchang No. 1 treatment in IBS-D rats.

  • Pathological alterations in colon tissue were examined using hematoxylin and eosin (H&E) staining.
  • Histological assessment was used to confirm the reduction in low-grade colonic inflammation associated with treatment.
  • Findings were consistent with the molecular and microbiota data supporting the formula's therapeutic efficacy.

What This Means

This research examined whether a traditional Chinese medicine formula called Jianchang No. 1 could treat irritable bowel syndrome with diarrhea (IBS-D) in rats, and if so, how it works. Researchers created IBS-D in rats by combining psychological stress (restraint and water avoidance stress) with a laxative (senna decoction), then treated the rats with the formula and measured multiple outcomes including body weight, stool water content, pain sensitivity in the gut, tissue damage, bacterial populations in the gut, and molecular markers of inflammation. The study found that Jianchang No. 1 improved multiple IBS-D symptoms: treated rats gained weight back, had less watery stools, and showed a higher pain threshold in the gut. At the molecular level, the formula reduced the levels of several proteins that drive inflammation (including IL-1β, IL-6, and TNF-α) while increasing an anti-inflammatory protein (IL-10). It also strengthened the physical barrier of the intestinal wall by increasing proteins called ZO-1 and occludin, which act like 'seals' between intestinal cells. Additionally, the formula restored healthier and more diverse gut bacterial communities and reduced activity in a key inflammation-triggering molecular pathway (the LPS-TLR2/4-MyD88-NF-κB axis). This research suggests that Jianchang No. 1 works through multiple complementary mechanisms simultaneously — rebalancing gut bacteria, reinforcing the intestinal barrier, and quieting inflammatory signaling — to reduce IBS-D symptoms in rats. These findings provide a scientific basis for understanding how this traditional formula may work and could support further research into its potential clinical use, though the results are currently limited to an animal model and would need to be validated in human clinical trials.

Have a question about this study?

Citation

Yutong L, Yan Y, Huiying X, Lei L, Fei G, Meijuan C. (2026). Jianchang No. 1 (1) formula alleviates irritable bowel syndrome with diarrhea improving gut microbiota and regulating toll-like receptors/nuclear factor-kappa B signaling pathway in bowel syndrome with diarrhea rats.. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. https://doi.org/10.19852/j.cnki.jtcm.2026.04.009